US2020270303A1PendingUtilityA1

Macrocyclic proline derived hcv serine protease inhibitors

79
Assignee: ENANTA PHARM INCPriority: Sep 21, 2010Filed: Dec 23, 2019Published: Aug 27, 2020
Est. expirySep 21, 2030(~4.1 yrs left)· nominal 20-yr term from priority
Inventors:Yat Sun OrJun MaGuoqiang WangJiang LongBin Wang
A61K 38/212A61K 38/215C07K 5/0808A61P 37/02A61K 31/395A61K 31/00A61K 38/00A61K 45/06A61K 31/4985C07K 14/811A61P 35/00C07D 498/22C07D 498/00A61K 31/495A61K 31/33C07K 5/06034A61K 39/00A61K 38/12C07K 5/123C07D 498/18A61P 31/10A61P 43/00A61P 31/14C07K 5/0827C07K 5/0823A61P 31/04C07D 498/12A61P 31/12A61P 1/16
79
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Claims

exact text as granted — not AI-modified
1 - 26 . (canceled) 
     
     
         27 . A compound selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
     
     
         28 . The compound of claim  1 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
     
     
         29 . The compound of claim  1 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
     
     
         30 . The compound of claim  1 , wherein the compound is:

Join the waitlist — get patent alerts

Track US2020270303A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.